Early Glargine
ApprovedSmall molecule
Early Glargine is one of 13 small molecule programs targeting Diabetic Ketoacidosis. It is currently in Approved.
1
Indications
2
Total Trials
1
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
24 competitors in Diabetic Ketoacidosis
#DrugCompanyPhaseTrials
1Insulin Therapy
SanofiPhase 2
Early Glargine
TThe Cleveland Clinic
Approved
SGLT-2 Inhibitor
SSheffield Teaching Hospitals NHS Foundation Trust
Phase 2
Reamberin
PPOLYSAN Scientific & Technological Pharmaceutical Company
Phase 3
Arginine Hydrochloride
TThe First Affiliated Hospital of Zhengzhou University
Phase 2
Plasma-Lyte 148
TThe George Institute
Phase 3
Jardiance
Boehringer IngelheimPreclinical
Glargine
Eli LillyPreclinical
Degludec
Eli LillyPreclinical
DPP-4 Inhibitors
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Early Glargine. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Approved[1]
- Company
- TThe Cleveland Clinic